Equillium Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

EquilliumDer Gewinn des Unternehmens wird voraussichtlich um 28.2% pro Jahr sinken, während der Jahresumsatz voraussichtlich um 8.3% pro Jahr wachsen wird. Der Gewinn pro Aktie wird voraussichtlich zurückgehen.

Wichtige Informationen

-28.2%

Wachstumsrate der Gewinne

-15.5%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.3%
Wachstumsrate der Einnahmen	8.3%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	14 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Why Investors Shouldn't Be Surprised By Equillium, Inc.'s (NASDAQ:EQ) 35% Share Price Plunge

Nov 16

Earnings Release: Here's Why Analysts Cut Their Equillium, Inc. (NASDAQ:EQ) Price Target To US$6.06

Aug 12

Broker Revenue Forecasts For Equillium, Inc. (NASDAQ:EQ) Are Surging Higher

May 03

Does Equillium (NASDAQ:EQ) Have A Healthy Balance Sheet?

Mar 26

Equillium GAAP EPS of -$0.41 in-line

Aug 15

Equillium CEO Bruce Steel - Drugs For Autoimmune, Inflammatory Disorders (Video)

Oct 08

Is Equillium, Inc.'s (NASDAQ:EQ) Shareholder Ownership Skewed Towards Insiders?

Mar 09

Equillium prices $30M registered direct offering

Feb 04

Equillium (EQ) Investor Presentation - Slideshow

Dec 04

How Much Of Equillium, Inc. (NASDAQ:EQ) Do Insiders Own?

Nov 24

FDA gives green signal to Equillium's late-stage COVID-19 trial

Oct 30

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:EQ - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	13	-36	-27	-27	2
12/31/2025	N/A	-39	-26	-26	4
12/31/2024	37	-14	-8	-15	2
9/30/2024	46	-5	-22	-21	N/A
6/30/2024	43	-8	-16	-16	N/A
3/31/2024	38	-12	-23	-23	N/A
12/31/2023	36	-13	-22	-22	N/A
9/30/2023	43	-8	12	12	N/A
6/30/2023	34	-18	0	0	N/A
3/31/2023	25	-29	-5	-5	N/A
12/31/2022	16	-62	-9	-9	N/A
9/30/2022	N/A	-76	-47	-47	N/A
6/30/2022	N/A	-72	-41	-41	N/A
3/31/2022	N/A	-67	-37	-36	N/A
12/31/2021	N/A	-39	-32	-32	N/A
9/30/2021	N/A	-37	-30	-30	N/A
6/30/2021	N/A	-34	-28	-28	N/A
3/31/2021	N/A	-31	-26	-26	N/A
12/31/2020	N/A	-30	-25	-25	N/A
9/30/2020	N/A	-28	-26	-25	N/A
6/30/2020	N/A	-28	-25	-25	N/A
3/31/2020	N/A	-27	-25	-25	N/A
12/31/2019	N/A	-26	-23	-23	N/A
9/30/2019	N/A	-23	-18	-18	N/A
6/30/2019	N/A	-22	-15	-15	N/A
3/31/2019	N/A	-18	-11	-11	N/A
12/31/2018	N/A	-13	-8	-8	N/A
9/30/2018	N/A	-10	-4	-4	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: EQ wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: EQ wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: EQ wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: EQDie Einnahmen des Unternehmens (8.3% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (8.9% pro Jahr).

Hohe Wachstumseinnahmen: EQDie Einnahmen des Unternehmens (8.3% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von EQ in 3 Jahren voraussichtlich hoch sein wird

Equillium Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased by 49% to US$3.33

Consensus revenue estimates fall by 27%

Consensus revenue estimates increase by 35%

Forecast to breakeven in 2024

Forecast to breakeven in 2024

Price target increased by 9.5% to US$6.75

Recent updates

Why Investors Shouldn't Be Surprised By Equillium, Inc.'s (NASDAQ:EQ) 35% Share Price Plunge

New major risk - Financial position

Third quarter 2024 earnings released: EPS: US$0 (vs US$0.11 loss in 3Q 2023)

Price target decreased by 49% to US$3.33

Consensus revenue estimates fall by 27%

Lacklustre Performance Is Driving Equillium, Inc.'s (NASDAQ:EQ) 28% Price Drop

Consensus revenue estimates increase by 35%

Forecast to breakeven in 2024

New minor risk - Shareholder dilution

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

New major risk - Financial position

New major risk - Share price stability

Equillium, Inc. Announces Positive Interim Analysis from Phase 3 Equator Study of Itolizumab in Acute Graft-Versus-Host Disease

Equillium Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement

Benign Growth For Equillium, Inc. (NASDAQ:EQ) Underpins Stock's 54% Plummet

Equillium, Inc. Announces Topline Data from Its Phase 2, Single Dose, Proof-Of-Concept Study of Eq101

Equillium, Inc. Announces Interim Enrollment Achieved in Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease

New minor risk - Profitability

Forecast to breakeven in 2024

First quarter 2024 earnings released: US$0.078 loss per share (vs US$0.11 loss in 1Q 2023)

We Think Equillium (NASDAQ:EQ) Needs To Drive Business Growth Carefully

Price target increased by 9.5% to US$6.75

Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1B Equalise Study of Itolizumab in Lupus Nephritis

Consensus EPS estimates fall by 188%

Little Excitement Around Equillium, Inc.'s (NASDAQ:EQ) Revenues

New major risk - Share price stability

Equillium Announces Update on Multi-Cytokine Inhibitors EQ101 & EQ102 in Development for Alopecia Areata and Celiac Disease

New minor risk - Share price stability

Price target decreased by 10% to US$6.17

Equillium, Inc. Presents Positive Data from Phase 1B EQUALISE Study At the 2023 Annual Meeting of the American College of Rheumatology

Equillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of Nephrology

Equillium Gets an Additional 180-Day Grace Period to Regain Compliance with the Minimum Bid Price Requirement

Consensus revenue estimates increase by 23%

Analyst Forecasts For Equillium, Inc. (NASDAQ:EQ) Are Surging Higher

Earnings Release: Here's Why Analysts Cut Their Equillium, Inc. (NASDAQ:EQ) Price Target To US$6.06

Equillium, Inc. Promotes Maple Fung to the Position of Chief Medical Officer

Equillium, Inc. (NasdaqGM:EQ) announces an Equity Buyback for $7.5 million worth of its shares.

Consensus revenue estimates increase by 187%

Broker Revenue Forecasts For Equillium, Inc. (NASDAQ:EQ) Are Surging Higher

Consensus revenue estimates increase by 17%

Does Equillium (NASDAQ:EQ) Have A Healthy Balance Sheet?

Biocon Limited in Collaboration with Equillium, Inc. Initiate Phase 2 Clinical Study of Itolizumab in Patients with Ulcerative Colitis

Price target decreased to US$12.00

Insufficient new directors

Equillium, Inc. Announces Initiation of Phase 2 Study of Eq101 A First-In-Class Multi-Cytokine Inhibitor of Il-2, Il-9 and Il-15 Targeting Alopecia Areata

Equillium Announces Initiation of Phase 1 study of EQ102, A First-in-Class Multi-Cytokine Inhibitor of IL-15 and IL-21 Targeting Celiac Disease

Price target decreased to US$12.00

Price target increased to US$14.00

Equillium, Inc. Reports Interim Results from the Type B Portion of the EQUALIZE Study Evaluating Itolizumab

Equillium, Inc. (NasdaqGM:EQ) entered into a definitive merger agreement to acquire Metacrine, Inc. (NasdaqCM:MTCR).

Equillium GAAP EPS of -$0.41 in-line

Insufficient new directors

Price target increased to US$13.75

Equillium, Inc., Annual General Meeting, May 24, 2022

Equillium, Inc. Announces Initiation of the Phase 3 EQUATOR Study of Itolizumab in First-line Acute Graft-Versus-Host Disease

Equillium, Inc. Appoints Barbara Troupin to its Board of Directors and as Member of Nominating and Corporate Governance Committee

Price target decreased to US$12.50

Equillium, Inc. (NasdaqGM:EQ) completed the acquisition of Bioniz Therapeutics, Inc. from Kevin Green for $330 million.

Equillium Announces Data from Phase 1B Equip Study in Patients with Uncontrolled Asthma

Senior VP & COO notifies of intention to sell stock

Equillium CEO Bruce Steel - Drugs For Autoimmune, Inflammatory Disorders (Video)

Equillium Announces Update to EQUALISE Study of Itolizumab in Patients with Systemic Lupus Erythematosus and Lupus Nephritis

Equillium, Inc. Announces Plans to Initiate Phase 3 Pivotal Study of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease Following End-of-Phase 1 Meeting with the FDA

Equillium, Inc.(NasdaqGM:EQ) dropped from Russell Microcap Value Index

Equillium Inc Announces Positive Topline Results from the EQUATE Study in First-line Treatment of Acute Graft-Versus-Host Disease

Equillium Presents Data on Target Engagement and Modulation of Cd6 on T Cells with Itolizumab at the International Society for Advancement of Cytometry

Chief Scientific Officer & Director exercised options and sold US$138k worth of stock

Price target decreased to US$13.75

Equillium Announces Oral Presentation Highlighting Positive Data from the EQUATE Study in Acute Graft-Versus-Host Disease at the EHA2021 Virtual Congress of the European Hematology Association